Chang C.-H.Lee C.-H.JANN-YUAN WANG2020-08-132020-08-1320170732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85017648983&doi=10.1200%2fJCO.2016.68.5842&partnerID=40&md5=bf416f9851f31ac9954cdbdd3e8343a5https://scholars.lib.ntu.edu.tw/handle/123456789/512431[SDGs]SDG2[SDGs]SDG3epidermal growth factor receptor; erlotinib; gefitinib; erlotinib; gefitinib; quinazoline derivative; cancer chemotherapy; cancer patient; cancer recurrence; cancer staging; cancer survival; comparative effectiveness; drug efficacy; gene mutation; human; Letter; lung adenocarcinoma; maximum tolerated dose; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); treatment duration; lung adenocarcinoma; lung tumor; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolinesletter10.1200/JCO.2016.68.5842281658952-s2.0-85017648983